A top can­cer R&D ex­ec at Genen­tech joins the ex­o­dus, jump­ing to a mar­quee Chi­na biotech as the new on­col­o­gy chief, deal­mak­er

Last year
People

Covid-19 roundup: Pfiz­er and Mod­er­na take their vac­cines to the EMA; Chief of Staff Mark Mead­ows calls Hahn to White House — re­port

Last year
Coronavirus

Re­gen­eron teams with gene ther­a­py pi­o­neer James Wil­son, adapt­ing its Covid-19 an­ti­body cock­tail to an AAV-based nasal spray

Last year
Deals
Coronavirus

FDA of­fers ‘break­through’ sta­tus for a HER2xHER2 bis­pe­cif­ic at the top of Zymeworks’ pipeline

Last year
R&D

As­traZeneca CEO So­ri­ot plans new study to test that con­tro­ver­sial 90% ef­fi­ca­cy fig­ure, wait­ing for US da­ta be­fore go­ing to FDA

Last year
Coronavirus

Mod­er­na cal­i­brates fi­nal Covid-19 vac­cine ef­fi­ca­cy at 94.1% — and to­day it's gun­ning for the EUA

Last year
R&D
Coronavirus

With ad­u­canum­ab caught on a cliff, Bio­gen’s Michel Vounatsos bets bil­lions on an­oth­er high-risk neu­ro play

Last year
Deals

Af­ter Ko­dak de­ba­cle, US lends $1.1B to a syn­thet­ic bi­ol­o­gy com­pa­ny and their big Covid-19, mR­NA plans

Last year
Outsourcing
Coronavirus

Covid-19 roundup: Eu­rope pur­chas­es 80M dos­es of Mod­er­na's vac­cine; CO­V­AXX se­cures $2.8B in emerg­ing mar­ket pre-or­ders

Last year
Coronavirus

Vas Narasimhan's 'Wild Card' drugs: No­var­tis CEO high­lights po­ten­tial jack­pots, as well as late-stage stars, in R&D pre­sen­ta­tion

Last year
R&D

Covid-19 roundup: Rus­sia prices vac­cine 't­wo or more times cheap­er' than mR­NA shots; Sino­vac PhI­II da­ta ex­pect­ed in ear­ly De­cem­ber

Last year
Coronavirus

Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

Last year
Pharma
FDA+

Bob Nelsen rais­es $800M and re­cruits a star-stud­ded board to build the 'Fox­con­n' of biotech

Last year
Startups

Tech bil­lion­aire Pe­ter Thiel backs a lead­ing psy­che­del­ic drug de­vel­op­er

Last year
Financing

In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

Last year
Deals
Coronavirus

As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

Last year
Coronavirus

Jen­nifer Zi­olkows­ki re­signs from CFO post at Sol­id Bio­sciences; Sean Bo­hen's Ole­ma On­col­o­gy adds San­dra Horn­ing to board of di­rec­tors

Last year
Peer Review

Pfiz­er and BioN­Tech are send­ing the first Covid-19 vac­cine to the FDA to­day

Last year
Coronavirus

Sean Bo­hen hauls in a mul­ti­mil­lion-dol­lar wind­fall as his new­ly adopt­ed biotech bags a $209M-plus IPO

Last year
Financing

Gilead touts piv­otal da­ta for new kind of HIV ther­a­py, open­ing to­wards large po­ten­tial mar­ket

Last year
R&D

Phar­ma lob­by­ist and long­time Biden loy­al­ist Steve Ric­chet­ti joins the in­ner cir­cle head­ed to the White House as drug pric­ing re­mains a hot top­ic

Last year
People
Pharma

The pri­ma­ry failed. The key sec­ondary failed. But this biotech still be­lieves it can win an FDA OK in ALS

Last year
R&D

Bris­tol My­er­s' $9 Cel­gene CVR is tee­ter­ing on the brink of dis­as­ter as the FDA de­lays the liso-cel ap­pli­ca­tion yet again

Last year
FDA+

One of biotech's flashiest star­tups is fi­nal­ly get­ting some com­pe­ti­tion from a pi­o­neer in a brand new field

Last year
Startups
First page Previous page 113114115116117118119 Next page Last page